TCEAL9 and acute myeloid leukemia: In agreement with the results from our pipeline, high expressers demonstrated lower survival rates in both cohorts after balancing (median OS = 347.25 vs 691.14, p = 0.01621 and 496.33 vs 1180.73, p = 0.01478) (Fig. S1), thus suggesting that the sole expression of WBP5 could serve as a reliable inferior predictor for AML.